New immune cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT05020444
Summary
This early-stage trial is testing a new type of CAR T-cell therapy called TriPRIL for adults with multiple myeloma that has returned or stopped responding to standard treatments. Researchers will give patients a single infusion of their own modified immune cells to try to fight the cancer, while carefully monitoring for side effects. The main goal is to find the safest dose before testing if it helps control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.